Cadrenal Therapeutics (CVKD) Operating Expenses (2022 - 2026)

Cadrenal Therapeutics has disclosed Operating Expenses across 5 years of filings, most recently posting $3.3 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 10.55% year-over-year to $3.3 million; the TTM figure through Jun 2026 stood at $12.0 million (up 15.21% YoY), while the FY2023 annual figure was $7.6 million, up 182.53% from the prior year.
• Operating Expenses came in at $3.3 million for Q2 2026 at Cadrenal Therapeutics, down from $3.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $4.2 million in Q1 2023 to a low of $170521.0 in Q1 2022.
• Average Operating Expenses over 5 years is $1.9 million, with a median of $1.3 million recorded in 2023.
• Year-over-year, Operating Expenses surged 2363.18% in 2023 and sank 58.2% in 2024.
• Over 5 years, Operating Expenses stood at $1.1 million in 2022, then gained by 17.46% to $1.3 million in 2023, then jumped by 94.64% to $2.5 million in 2024, then surged by 51.8% to $3.7 million in 2025, then declined by 10.55% to $3.3 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $3.3 million in Q2 2026, $3.7 million in Q2 2025, and $2.5 million in Q3 2024.